Can The Medicines Company Rebound From A Phase III Blow?
This article was originally published in The Pink Sheet Daily
Executive Summary
Antithrombotic cangrelor fails against Plavix in angioplasty, but the company says the drug’s profile lends to an indication as a bridge therapy for surgery patients who can’t stay on clopidogrel.